Advertisement

Topics

Global CEO Initiative on Alzheimer’s Disease and Optum Labs Company Profile

07:17 EST 15th December 2018 | BioPortfolio


News Articles [3928 Associated News Articles listed on BioPortfolio]

Global CEO Initiative: Andrea Pfeifer & George Vradenburg. Working together on the global fight to stop Alzheimer’s disease

In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Andrea Pfeifer & George Vradenburg from the Global CEO Initiative

Businessman issues global, multimillion dollar (USD) challenge for Alzheimer's solutions

(University of Texas at San Antonio) To expand the understanding and explanation of Alzheimer's disease, U.S. businessman James Truchard has given a $5 million USD gift to The University of Texas at S...

Global Alzheimer’s Disease Epidemiology, Patient Flow, Prevalence and Diagnosed & Treated Patients Analysis – 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Alzheimer’s Disease Epidemiology and Patient Flow Analysis – 2018” report has been added to ResearchAndMarkets.com’s offeri...

Alzheimer Disease | Medscape

Review in-depth clinical information, latest medical news, and guidelines on Alzheimer Disease. Recognize the causes of Alzheimer Disease and signs of Alzheimer Disease, including dementia.

Global Alzheimer's Disease Market and Competitive Landscape 2014-2023: Pipeline, Epidemiology, ...

DUBLIN, Oct 30, 2018 /PRNewswire/ -- The "Global Alzheimer's Disease Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. Global Alzheimer's Read more....

Update on Phase III clinical trials of lanabecestat for Alzheimer's disease

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzh...

Study partners: essential collaborators in discovering treatments for Alzheimer’s disease

Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer’s disease by 2025.

Classifying Alzheimer's patients in 6 subgroups

Researchers studying Alzheimer's disease have created an approach to classify patients with Alzheimer's disease, a finding that may open the door for personalized treatments. "Alzheimer's, like breas...

Drugs and Medications [430 Associated Drugs and Medications listed on BioPortfolio]

Sure antiperspirant deodorant unscented [Idelle Labs, Ltd]

Sure Aerosol Antiperspirant Deodorant Unscented

Sure antiperspirant deodorant regular [Idelle Labs, Ltd]

Sure Aerosol Antiperspirant Deodorant Regular Scent

Ammens medicated powder shower fresh formula [Idelle Labs, Ltd]

Ammens Medicated Powder Shower Fresh Formula

Ammens medicated powder original [Idelle Labs, Ltd]

Ammens Medicated Powder

Brut anti-perspirant and deodorant [Idelle Labs, Ltd]

Brut Anti-perspirant and Deodorant

PubMed Articles [4898 Associated PubMed Articles listed on BioPortfolio]

Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite, longitudinal, observational stud...

Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials.

We conducted Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) and compared the basic characteristics and progression profiles with those of ADNI in North America.

Using high-dimensional machine learning methods to estimate an anatomical risk factor for Alzheimer's disease across imaging databases.

The main goal of this work is to investigate the feasibility of estimating an anatomical index that can be used as an Alzheimer's disease (AD) risk factor in the Women's Health Initiative Magnetic Res...

Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort.

Alzheimer's disease (AD) is a major public health priority with a large socioeconomic burden and complex etiology. The Alzheimer Disease Metabolomics Consortium (ADMC) and the Alzheimer Disease Neuroi...

Elevated CSF GAP-43 is Alzheimer's disease specific and associated with tau and amyloid pathology.

The level of the presynaptic protein growth-associated protein 43 (GAP-43) in cerebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer's disease (AD) and thus may serve as an o...

Clinical Trials [5019 Associated Clinical Trials listed on BioPortfolio]

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used...

Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continu...

Effects of ONO-2506PO in Patients With Alzheimer's Disease

The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients a...

Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's

Determine effect and duration of effect of timed therapeutic light compared to control light on parameters of circadian rhythmicity, physiologic plasticity, sleep, and global function in w...

Companies [2751 Associated Companies listed on BioPortfolio]

Global CEO Initiative on Alzheimer’s Disease and Optum Labs

Optum Labs

Optum Labs was established through a partnership between Optum, a leading information and technology-enabled health services business, and Mayo Clinic, a nonprofit worldwide leade...

Optum Jeffrey Smith Optum (773) 907-0860jeffrey.p.smith@optum.com

Optum (www.optum.com) is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. Optum c...

Optum and QSSI, Inc.

Optum is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. With more than 50,000 people w...

Optum / Mayo Clinic

Optum (www.optum.com) is a leading information and technology-enabled health services business dedicated to helping make the health system work better for everyone. Optum c...

More Information about "Global CEO Initiative on Alzheimer’s Disease and Optum Labs" on BioPortfolio

We have published hundreds of Global CEO Initiative on Alzheimer’s Disease and Optum Labs news stories on BioPortfolio along with dozens of Global CEO Initiative on Alzheimer’s Disease and Optum Labs Clinical Trials and PubMed Articles about Global CEO Initiative on Alzheimer’s Disease and Optum Labs for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Global CEO Initiative on Alzheimer’s Disease and Optum Labs Companies in our database. You can also find out about relevant Global CEO Initiative on Alzheimer’s Disease and Optum Labs Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record